[Prostatilen effects on voiding disorders in patients with benign prostatic hyperplasia].
The authors review the experience with prostatilen treatment gained in the urological clinic of the St-Petersburg State Medical University and analyze treatment outcomes for 96 patients with benign prostatic hyperplasia (BPH) aged from 51 to 89 years. Prostatilen proved its efficacy in relieving manifestations of infravesical obstruction in BPH, therefore, prostatilen administration in the treatment of patients with initial or moderate subjective and objective symptoms is justified. Dimexide suppositoria containing 30 mg of prostatilen are preferable.
Al'-Shukri
S Kh
SKh
Gorbachev
A G
AG
Borovets
S Iu
SIu
Belousov
V Ia
VIa
Kuz'min
I V
IV
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
D010455:Peptides; C069549:prostatilen